Research progress of bispecific antibodies in the treatment of gastric cancer

Gastric cancer is a malignant tumor that causes death worldwide, especially in developing countries, and the incidence and mortality of gastric cancer are very high. Most patients with gastric cancer are in the advanced stage, and the limited surgical and chemotherapy methods have limited therapeutic effects, so it is of great significance to explore new treatment methods. In the past 10 years, the mature application of tumor molecular mechanism research and antibody engineering technology has made bispecific antibodies have broad application prospects as new targeted therapy drugs in tumor treatment. For example, in HER2-negative gastric cancer patients, HER2-negative bispecific antibodies such as cadonilimimab can be combined with chemotherapy to enhance the anti-tumor immune response in the treatment of HER2-negative advanced gastric cancer or gastroesophageal junction adenocarcinoma. In summary, bispecific antibodies are a new class of targeted therapy drugs, which have broad application prospects in the treatment of gastric cancer.